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ABSTRACT
Foster, Micah John. The Difference In Physiological Parameters Following An Exercise
Intervention In Breast Cancer Survivors On A Single Chemotherapy Drug Versus
Combination Chemotherapy Drugs. Published Master of Science thesis,
University of Northern Colorado, 2010.
Exercise has become an important part of cancer rehabilitation as the incidence of
breast cancer is increasing and the mortality rate is decreasing. Breast cancer
chemotherapy treatment induces a physical demand on the body while exercise counter
balances symptoms of chemotherapy treatment. The purpose of this investigation was to
determine the effects an exercise intervention has on breast cancer survivors who have
received a single chemotherapy drug versus combination chemotherapy drugs. A
secondary purpose was to determine any differences in chemotherapy categories.
Participants were chosen that had single drug treatment (n = 34) and combination drug
treatment (n = 20). Groups completed a pre-physiological assessment followed by an
exercise intervention. Following the exercise intervention, a post-assessment was
obtained. The protocol for all assessments was the same for all breast cancer survivors,
but each exercise intervention was individualized. Within single and combination
chemotherapy groups pre- to post-assessment, results showed significant improvement
(P<0.05) in pulmonary function [FVC% - Single – change (2.04%) and Combination –
change (5.66%)] and [FEV1% - Single – change (3.87%) and Combination – change
(6.60%)], chest press [Single – change (6.50%) and Combination – change (6.50%)], lat
pulldown [Single – change (9.70%) and Combination – change (6.90%)], shoulder press
[Single – change (9.20%) and Combination – change (9.75%)], and sit-and-reach [Single
– change (0.40%) and Combination – change (0.55%)]. Resting heart rate was

significantly (P<0.05) improved only in the combination group – change (-6.60%). The
data suggest that exercise is beneficial for breast cancer survivors whether on a single
chemotherapy drug or on a combination of multiple chemotherapy drugs. Additionally,
no significant differences were found between chemotherapy categories or the interaction
between therapy and drug categories.
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CHAPTER I
INTRODUCTION
Breast cancer is the most common cancer among women, accounting for roughly
1 in 4 cancers diagnosed in women in the United States, with the exception of skin
cancer. (Breast Cancer Facts & Figures, 2009-1010) Since 1990, women in the United
States under the age of 50 have shown a drop in death rates of 3.2% per year and those 50
and older have shown a drop of 2% per year. (Cancer Facts and Figures, 2010) In
addition, from 1999-2005, the incidence of female breast cancer has declined 2.2% per
year, after incessantly increasing for over two decades. (Cancer Facts & Figures, 2010)
Risk factors include age, gender, family history, postmenopausal obesity, alcohol
consumption, physically inactive, and the use of combined estrogen and progestin
menopausal hormones. (Breast Cancer Facts & Figures, 2009-2010)
Chemotherapy treatments with single-agent, sequential single-agent, and
combination chemotherapy regimens have had a significant physiological and
psychological impact on breast cancer survivors. In a review by Cardoso, Bedard, Winer,
Pagani, Senkus-Konefka, Fallowfield, et al. (2009), it was suggested that there is an
improvement in overall survival rate (P<0.001) with combination versus single-agent
chemotherapy in metastatic breast cancer. Francis, Crown, Di Leo, Buyse, Balil,
Andersson, et al. (2008) found that the use of sequential chemotherapy treatment was
better in disease-free survival compared to concurrent chemotherapy treatment. Carlson
& Telli, (2009) suggested that while combination chemotherapy is associated with greater
toxicity than with sequential chemotherapy, sequential chemotherapy is the preferred
approach for most patients. Mauri, Polyzos, Salanti, Pavlidis, and Ioanndis (2008) found
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that anthracycline regimens compared with single-agent chemotherapy with
nonanthracycline drugs had a 22-33% relative risk reduction in mortality. Jones (2008)
suggested superior survival outcomes with taxane-based regimens, nonanthracyclines,
and trastuzumab. In a study by Miles, von Minckwitz, and Seidman (2002), combination
versus sequential chemotherapy was found to show significant (P<0.05) improvement in
response rate, median time to progression, and median overall survival. However, there
has not been enough evidence to establish a universal consensus on which chemotherapy
treatment regimen is the most effective.
Exercise interventions used in cancer rehabilitation settings have had a
physiological impact on breast cancer survivors. In a review by Spence, Heesch, and
Brown (2009), improvements were found in physical performance (P<0.05) and walking
(P<0.01). Vallance, Plotnikoff, Karvinen, Mackey, and Courneya (2010) found that
breast cancer survivors who met the physical activity guidelines at baseline (P<0.001)
and post intervention (P<0.001), had a greater likelihood of meeting the physical activity
guidelines at 6 months follow-up. Sprod, Hsieh, Hayward, and Schneider (2010) found
significant (P<0.05) improvements in cardiovascular endurance in breast cancer survivors
undergoing 3- and 6-month individualized exercise interventions. Additional
improvements (P<0.05) were shown for breast cancer survivors exercising for 6-months
in pulmonary function and muscular endurance.
Exercise has also been found to reduce many of the psychological side effects
associated with breast cancer. Blanchard, Courneya, and Laing (2001) found that acute
exercise was an effective intervention in reducing (P<0.03) the state anxiety in breast
cancer survivors. Brown et al. (2009) found improvements in quality of life and fatigue,
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while Vallance et al. (2010) found significant improvements in physical activity behavior
(P<0.001), psychosocial functioning (P<0.001), and motivation (P<0.001), and Sprod et
al. (2010) found significant (P<0.05) improvements in fatigue and symptoms of
depression.
The combination of chemotherapy and exercise treatment with breast cancer
survivors has a significant impact on physiological and psychological parameters and
side effects. However, more information is needed regarding chemotherapy regimens,
chemotherapy categories, and exercise to determine any significant effects on breast
cancer. Additionally it is necessary to establish whether one chemotherapy treatment
regimen is better in regards to the outcomes of exercise assessments.
Statement of Purpose
The purpose of this research was to determine the differences in physiological
parameters following an exercise intervention in female breast cancer survivors on a
single chemotherapy drug versus combination chemotherapy drugs. A secondary
purpose was to determine any differences in chemotherapy categories.
Research Hypotheses
H1: The main hypothesis for this investigation was that breast cancer survivors
receiving single-agent and sequential single-agent chemotherapy treatment would
show significantly greater results in physiological parameters measured in preand post-exercise assessments compared to breast cancer survivors receiving
combination chemotherapy.
H2: The chemotherapy categories will show significant differences in
physiological parameters.
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H3: Exercise will enhance performance pre- to post-exercise intervention.
Assumptions
This study was conducted under the assumption that participants did not engage in

activities other than those exercises performed under the supervision of a cancer exercise
rehabilitation specialist at the Rocky Mountain Cancer Rehabilitation Institute.
Limitations
There were several limitations with this study. First, the breast cancer survivors
weren’t all at the same stage of recovery. The exercise intervention was individualized
and therefore clients did not perform the same exercises.
Significance of the Study
The relationship between single-agent, sequential single-agent, and combination
chemotherapy treatment with female breast cancer survivors and overall survival,
progression-free survival, disease-free survival, and time to treatment failure has been
established (Biganzoli et al., 2002; Chan et al., 1999; Citron et al., 2003; Forbes et al.,
(2008); Henderson et al., 2003; Jones et al., 2006; Jones et al., 2005; Mamounas et al.,
2005; Marty et al., 2005; Miller et al., 2007; Nabholtz et al., 2003; Paridaens et al., 2000;
Piccart-Gebhart et al., 2006; Robert et al., 2006; Seidman et al., 2008; Slamon et al.,
2001; Sledge et al., 2003; Sparano et al., 2008). The physiological benefits of an exercise
intervention for female breast cancer survivors receiving chemotherapy treatment have
also been established (Campbell et al., 2005; Courneya et al., 2003; Drouin et al., 2006;
Hsieh et al., 2008; Kolden et al., 2002; Matthews et al., 2007; Mock et al., 2004; Mutrie
et al., 2007; Nikander et al., 2007; Pinto et al., 2003; Schneider et al., 2007).
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However, no research has been found that determines the physiological

differences in response to single-agent, sequential single-agent, and combination
chemotherapy treatment or determining if differences exist between categories of
chemotherapy drugs. Therefore, this study was designed to determine the physiological
alterations that occur with exercise in breast cancer survivors who received varying
regimens and categories of chemotherapy drugs.
Definition of Terms
Adenocarcinoma (AC). A cancer histotype that originates in glandular tissue –
the part of an epithelial tissue which includes skin, glands, and other tissues that line the
organ/body’s cavities.
Adjuvant setting. Additional treatment given after surgery.
Apoptosis. Digestion by phagocytes of cell fragments from destroyed cells.
Anaphase. Third stage of mitosis in which a full set of daughter chromosomes
move toward each pole of a cell.
Anaplasia. A reversion of differentiation in cells and is characteristic of
malignant tumors.
Antineoplastics. Drugs that inhibit neoplasms.
Arthralgias. Joint pain due to injury, infection, illnesses, or allergic reaction to
medication.
Axillary lymph nodes. Small oval-shaped organs of the immune system located
in the armpit region of the body.
Biopsy-confirmed hyperplasia. The increase of cells especially atypical
hyperplasia.
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Bone marrow. Soft substance inside bones.
Cachexia. Weight loss.
Cell proliferation. Rapid cell reproduction.
Chemotherapy. Administration of cytotoxic chemicals to destroy malignant

tumor cells.
Comorbidity. The appearance of multiple illnesses.
Cytokinesis. The division of cytoplasm that occurs after the cell nucleus has
divided.
DNA (deoxyribonucleic acid). A nucleic acid found in all living cells; it carries
the organism’s hereditary information.
Drop Foot. Deficiency in dorsiflexion of the ankle and toes.
Dyspnea. Shortness of breath.
Filgrastim. A granulocyte colony-stimulating factor (G-CSF) analog used to
stimulate the proliferation and differentiation of granulocytes.
Forced Expiratory Volume (FEV1). Is the volume of air exhaled in the first
second after maximal inhalation.
Forced Vital Capacity (FVC). The maximal amount of air a person can expel
from the lungs after a maximum inspiration.
Genome. Entirety of an organism’s heredity.
Granulocytopenia. Neutrophil deficiency that reduces fight against infection,
basophils, and eosinophils.
Hematopoietic. Blood cell component formation.
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High breast tissue density. A mammographic measure of the amount of glandular

tissue relative to fatty tissue in the breast.
High bone mineral density. A routinely measured to identify women at increased
risk for osteoporosis.
Hyperplasia. An enlargement caused by increased cells.
Kinase. An enzyme that transfers phosphate groups from high-energy donor
molecules to specific substrates.
Leucopenia. Low white blood cell count.
Lymphatic system. Vessels transporting lymph.
Lymphedema. Swelling of subcutaneous tissues caused by obstruction of
lymphatic drainage.
Lymphocytes. Type of white blood cells.
Malignant tumor. An invasive tumor that has the competence to form metastic
colonies.
Mammogram. An x-ray of the breast.
Mastectomy. Surgical breast cancer treatment involving the removal of the breast
tissue while leaving the skin, nipple, pectoral muscles and lymph nodes.
Melanocytes. Malignant pigment-producing cells.
Metaphase. Second stage of mitosis.
Metastasis. The manifestation of a malignancy in a secondary growth in a new
location arising from the primary growth.
Mitosis. Process during which the chromosomes are redistributed to two daughter
nuclei; nuclear division. Consists of prophase, metaphase, anaphase, and telophase.
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Myalgias. Muscle pain from diseases and disorders.
Nadir. Low blood counts.
Necrosis. Cell death.
Neurons. Nerve cell.
Peripheral neuropathy. Nerve damage caused by injuries, infections, metabolic

problems and exposure to toxins.
Prophase. The first stage of mitosis, consisting of coiling of the chromosomes
accompanied by migration of the two daughter centrioles toward the poles of the cell, and
nuclear membrane breakdown.
Radiation. The process by which ionization displaces an electron form the
nucleus of an atom, resulting in an unstable atom, followed by the free atom being
accepted by another atom, thus becoming unstable.
RNA (ribonucleic acid). Nucleic acid that contains ribose and the bases A, G, C,
and U. Carries out DNA’s instructions for protein synthesis.
Sequential chemotherapy. Chemotherapy in which several agents are
administered one at a time rather than concurrently to optimize dosage and increase
patient tolerance.
Tachypnea. Rapid breathing.
Telophase. The final phase of mitosis; begins when migration of chromosomes to
the poles of the cell has been completed and ends with the formation of two daughter
nuclei.
Topoisomerase. Enzyme that unwind and wind DNA.
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CHAPTER II
REVIEW OF LITERATURE
Introduction
Cancer is a disease characterized by an abnormal regulation of cell growth

and reproduction that has the capability of metastasizing throughout the body.
(Brooks, Fahey, & Baldwin, 2005; Marieb & Hoehn 2007; Schneider, Dennehy, &
Carter, 2003) A number of factors need to be considered regarding the cause for
cancer. External factors are preventative determinants such as tobacco, infectious
organisms, chemicals, smoke, fumes, and radiation. On the other hand, internal
factors consist of inherited mutations, hormones, immune conditions, and mutations
arising from metabolic processes, which are all influential determinants of cancer.
(Cancer Facts & Figures, 2009)
Cancer Incidence
Approximately 77% of all cancers are diagnosed in persons 55 years of age
and older, yet anyone at anytime can be susceptible to cancer. (Cancer Facts &
Figures, 2009) The good news is that, according to The National Cancer Institute,
approximately 11.1 million Americans with a history of cancer were alive in 2005
and the number of cancer survivors is steadily increasing. According to Cancer Facts
and Figures (2009), approximately 1,479,350 new cases of cancer are expected in the
United States.
Cancer is often referred and classified as benign or malignant tumors.
Tumors are an abnormal growth of cells caused by abnormal regulation of cell
division. Benign tumors grow slowly and rarely cause death but are capable of
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damaging adjacent areas. Unlike malignant tumors, benign tumors don’t possess the
destructive potential and are well differentiated and well organized. (Brooks et al.,
2005; Schneider et al., 2003)
On the other hand, malignant tumors contain cancer cells and are very
unpredictable and unsettled in terms of organization compared to normal cells.
These tumors consist of a widely assorted arrangement of cells, cells with loss of
differentiation, anomalous (irregular) mitotic characteristics, increased invasiveness
throughout the body (metastasis), and a decreased sensitivity to drug exposure.
(Schneider et al., 2003) Malignant tumors are commonly susceptible to
metastasizing, where a secondary tumor from it’s original origin develops but its
location resides in another tissue elsewhere in the body. (Marieb & Hoehn, 2007;
Schneider et al., 2003) The process of metastasis arises due to the release of attached
tumor cells from the primary tumor, allowing entry into the circulation or lymphatic
system. (Marieb & Hoehn, 2007; Schneider et al., 2003) Next, the sub-endothelial
basement membrane of the distant tissue has the tumor cells adhere to it and the
entrance into new tissue is then permitted and proliferation and reproduction of new
cells form in the new tissue. Malignant tumors are also designed to pursue
aggressive cell proliferation, affect normal tissue and eventually terminate the host
tissue. (Brooks et al. 2005; Schneider et al., 2003) Malignant tumors are of a
disproportionate form and contain considerable amounts of necrotic areas because of
the compromised blood flow supply and lack of apoptosis. (Schneider et al., 2003)
The understanding of how a normal cell develops must first be established in order to
understand how cancer develops.
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Cell Division and Carcinogenesis
A normal cell in the body consists of two major parts, the nucleus and the

cytoplasm. The nucleus is the control center where chemical reactions and
reproduction of the cell are orchestrated. Vast quantities of deoxyribonucleic acid
molecules (DNA) called genes, reside in the nucleus of the cell. Genes control the
heredity passed on from parents to children. (Marieb & Hoehn, 2007) The body
contains somatic cells that can sustain trauma, disease, or damage to the cell. The
body is also capable of reproducing new cells in order to replace the compromised
cells. In addition, there is a large amount of cell reproduction that continuously
occurs in places like bone marrow and skin. Conversely, neurons and striated muscle
cells either have infrequent or no reproduction of new cells. The normal cell growth
and division consists of a cell cycle, which involves two phases, the interphase and
cell division (mitosis or M phase). (Schneider et al., 2003) The interphase is the
period beginning from cell formation to cell division consisting of 90% of the cell
cycle. Cell division is vital to the body’s growth and repairing of tissue and in most
body cells consists of two events, mitosis and cytokinesis. (Marieb & Hoehn, 2007)
Mitosis consists of a number of eloquent events where two daughter cells develop
from the mother cell. This goes into four phases involving the prophase, metaphase,
anaphase, and telophase where all of the phase’s transition into the other at a
continuous rate and the duration varies according to the type of cell. (Marieb, &
Hoehn, 2007) Cytokinesis, starts at a later time during the anaphase, and is finished
after the mitosis phase ends. The body’s cells contain pairs of chromosomes. Within
these pairs of chromosomes are genes made up of DNA molecules. These genes are
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responsible and considered the backbone for the creation of life through sending
messages to the chromosomes periodically instructing the body’s process of growth
and function. However, this isn’t always the case and unfortunately errors arise and
pose threats to reproduction. The body is capable of repairing some of the errors yet,
if they occur while in the stages of cell division, the cell’s genes can be compromised
causing mutations. This destructive shift can ultimately cause an abnormality among
the chromosome within the cancer cell and the cancer then starts to develop as the
abnormal chromosome begins to reproduce. (Schneider et al., 2003)
Carcinogenesis, which is defined as the steps in converting a normal cell into
a cancerous cell, is suggested to occur in two stages (initiation and promotion) with
the branching of substages. (Schneider et al., 2003) The effects carcinogens have on
the chromosomes components during the pre-initiation stage are protected. During
the first stage, which is the initiation phase, a carcinogen attacks a normal cell within
the genome of the cell, and the consequential mutated cell resorts to uncontrolled cell
division. (Cowan & Talaro, 2009; Schneider et al., 2003) Therefore, causing an
alteration or destruction among the DNA molecules of the cell or inhibition and
ultimately complete failure of the cell’s DNA repair system. (Cowan & Talaro,
2009; Schneider et al., 2003) However, an accumulation of up to ten mutations may
have to occur in order for a cell to become cancerous. (Schneider et al., 2003) The
DNA mutation is expressed as soon as the division of the cell takes place and the
second stage (promotion) is then initiated. (Schneider et al., 2003) Unrestrained cell
division, along with the promotion of tumor development begins and the cell genetic
information can be expressed or repressed. (Cowan & Talaro, 2009; Schneider et al.,
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2003) In the repressed state of a mutated gene, a normal function can take place but
the potential of expression is always in consideration. Cancer cells can reproduce at
any pace and the formation of tumors is the result. These tumors then form
throughout the body’s tissues and organs where a classification for the actual cancer
is then established. (Schneider et al., 2003)
Characteristics of Cancer Cells
There are a number of types of cancer, where tumors are named according to
the invaded tissue or organ within the body and the level of cell differentiation.
Specifically, there are five classes of cancer types and each has a very extensive
background. Carcinomas are tumors that originate in the epithelial cells (lining of all
tissues). (Saladin, 2010; Schneider et al., 2003) Melanomas are malignant tumors of
melanocytes that are commonly on the skin, but can be seen throughout the body.
Sarcomas are solid tumors that originate in connective tissue, bone, muscle, cartilage,
or fat. Leukemia is a cancer of the blood or bone marrow due to abnormal white
blood cell (leukocyte) proliferation. (Saladin, 2010; Schneider et al., 2003) Lastly,
lymphomas are malignant cancers of the lymphocytes resulting in an amplification of
lymph glands as well as other organs where the development of lymphocytes
normally occurs. (Saladin, 2010; Schneider et al., 2003)
Grading and Staging of Cancer Cells
The grading of tumors is established according to the tumor cells microscopic
appearance. This presents the level of undifferentiation (anaplasia) that exists within
the cells, where the less the cells are differentiated, the more malignant the cancer.
(Schneider et al., 2003) There are four classes of grading starting with grade I (low-
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grade) to grade IV (highest grade) when identifying the state of a tumor cell. A
grade I tumor cell is identified as a tumor with cells that are well differentiated,
resemble normal cells, are slow growing, and not very aggressive. Grades II and III
tumors have a moderate and poor status of differentiated cells. Grade IV tumors are
poorly differentiated, their cells are immature in nature, they complicate the
pinpointing of origin location within the tissue, are fast growing, and extremely
aggressive.
The term TNM Staging (tumor, nodes, metastasis) in cancer research is
widely used for clinical and pathological purposes in determining the cancer’s extent
and progression. (Schneider et al., 2003) In order to determine the proper therapy
for a cancer patient, the cancer’s anatomic status and extent must be established.
Through the use of TNM Staging, the higher the stage, the more the progression of
the cancer. The TNM Stage is categorized by the following: the letter (T) represents
the local tumors size, (N) represents the spread of the cancer to regional lymph
nodes, and (M) represents the presence or absence of distant metastasis. (Schneider
et al., 2003) According to Schneider et al. (2003), the TNM System has four stages
recognized within it involving the following:

•

Stage I signifies a mass limited to the organ of origin, no lymph node
involvement, and no metastasis.

•

Stage II signifies that the original tumor has spread into immediate
surrounding tissue and there is some lymph node involvement.
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•

Stage III signifies that tumors show an extensive primary lesion with
fixation to deeper structures, and lymph nodes exhibit malignant
invasion.

•

Stage IV signifies that distant metastases beyond the local site of the
primary tumor are evident.

Table 1 below displays the staging of the tumor; it’s size, lymph node involvement,
and whether there is metastasis.
Table 1. Basic Staging of the TNM System (Schneider et al., 2003)
Tumor Stage
Tumor Size
Lymph nodes?
Metastasis
I
<2 cm
None
None
II
2-5 cm
No, or yes on same side
None
III
>5 cm
Yes on same side
None
IV
Does not matter
Does not matter
Yes
Breast Cancer
Breast cancer is an uncontrolled growth of breast cells, as a result of
mutations, or abnormal changes in the genes responsible for regulating the growth of
cells. (Schneider et al., 2003) There are two main types of breast cancer, first, a
ductal carcinoma, which forms in the tubes (ducts) and transports milk from the
breast to the nipple. The second type, lobular carcinoma, forms in the lobules of the
breast where milk is formed. It has been suggested that over 95% of breast cancers
originate from the epithelial elements of the mammary gland and are
adenocarcinomas. (Manton, Akushevich, & Kravchenko, 2009) In 2009, the United
States had 192,370 new cases of breast cancer in women and 1,910 in men. Deaths
are projected at 40,170 females and 440 males. (Cancer Facts & Figures, 2009)
According to Cancer Facts & Figures (2009), breast cancer with the exception of skin

	
  

16	
  

cancers, is the most commonly diagnosed cancer among women in the United States.
Breast cancer is ranked as the second leading cause of death among women second to
lung cancer. However, from 1999-2005, incidences of female breast cancer have
declined 2.2% per year, after increasing for over two decades. In addition, since
1990 women under the age of 50 have shown a drop in death rates of 3.2% per year,
and those 50 and older a drop of 2% per year. (Cancer Facts & Figures, 2009)
According to Cancer Facts and Figures (2009), this decrease is due to the reduction in
the use of menopausal hormone therapy (MHT), formerly known as hormone
replacement therapy. This is due to the publication of results from the Women’s
Health Initiative in 2002, which associated MHT use to the increase of breast cancer
and heart disease.
Risk factors for breast cancer consist of age, family or personal history
(inherited genetic mutations in the breast), overweight or obesity after menopause,
the use of MHT (especially combined with estrogen and progestin therapy), physical
inactivity, smoking, and consumption of one or more alcoholic beverages per day.
(Cancer Facts & Figures, 2009; Marieb & Hoehn, 2007; Martini & Bartholomew,
2007; Saladin, 2010) In addition to these risk factors, there are other factors
considered to increase the risk for breast cancer. These involve high breast tissue
density, high bone mineral density, biopsy-confirmed hyperplasia, and high-dose
radiation to the chest, typically related to a medical procedure. (Saladin, 2010;
Cancer Facts & Figures, 2009)
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Categories and Staging of Breast Cancer
The detection of breast cancer is typically seen on a mammogram in an early

abnormal state, even before the possibility of it being physically felt by the woman or
health care professional. There are two types of mammograms that are available. The
first being a screening mammogram which is used to check for breast cancer in
women who have no signs or symptoms of the disease, and second a diagnostic
mammogram which is used to check for breast cancer after a lump or other sign or
symptom of the disease has been found. (Saladin, 2010; www.radiologyinfo.org) In
the case of a large tumor, the mass may be painless to the person in benign
conditions. (Cancer Facts & Figures, 2009) Less common symptoms involve
continual change in the breast, such as thickening, swelling, distortion, tenderness,
skin irritation, redness, or scaliness, or nipple abnormalities, such as ulceration,
retraction, or spontaneous discharge. (Saladin, 2010; Cancer Facts & Figures, 2009)
Table 2 describes the stage of breast cancer beginning with lowest, Stage 0 to the
highest, Stage IV, and a description of each stage. (www.breastcancer.org)
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Table 2. Breast Cancer Stages (www.breastcancer.org)
Stage
0
I
IIA

IIB

IIIA

IIIB

IIIC

IV

Definition
Cancer cells remain inside the breast duct, without invasion into
normal adjacent breast tissue.
Cancer is 2 centimeters or less and is confined to the breast (lymph
nodes are clear).
No tumor can be found in the breast, but cancer cells are found in
axillary lymph nodes (the lymph nodes under the arm) OR the
tumor measures 2 centimeters or smaller and has spread to the
axillary lymph nodes OR the tumor is larger than 2 but no larger
than 5 centimeters and has not spread to the axillary lymph nodes.
The tumor is larger than 2 but no larger than 5 centimeters and has
spread to the axillary lymph nodes OR the tumor is larger than 5
centimeters but has not spread to the axillary lymph nodes.
No tumor is found in the breast. Cancer is found in axillary lymph
nodes that are sticking together or to other structures, or cancer
may be found in lymph nodes near the breastbone OR the tumor is
any size. Cancer has spread to the axillary lymph nodes, which are
sticking together or to other structures, or cancer may be found in
lymph nodes near the breastbone.
The tumor may be any size and has spread to the chest wall and/or
skin of the breast AND may have spread to axillary lymph nodes
that are clumped together or sticking to other structures, or
inflammatory breast cancer is considered at least Stage IIIB.
There may either be no sign of cancer in the breast or a tumor may
be any size and may have spread to the chest wall and/or the skin of
the breast AND the cancer has spread to lymph nodes either above
or below the collarbone AND the cancer may have spread to
axillary lymph nodes or to lymph nodes near the breastbone.
The cancer has spread – or metastasized – to other parts of the
body.
Chemotherapy Treatment and Breast Cancer
Chemotherapy, also known as anti-cancer and antineoplastics, for it’s use in

cancer treatment began in the 1940’s with the use of nitrogen mustard therapy.
Dougherty, Gilman, Goodman, and Lindskog (1942-1943) first established nitrogen
mustard therapy as a cancer treatment however, there were no published studies
because of wartime military security considerations. Chemotherapy is designed and
used for curing a specific cancer; controlling tumor growth; tumor shrinkage before
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surgery or radiation therapy; and destroying cancer cells of microscopic proportion
that may be present after the known tumor is removed by surgery (adjuvant therapy
for preventing recurrence). The ultimate goal is to destroy the entirety of the tumor
cells with very little damage to the normal cells along with limiting destructive
effects on a normal cells function. However, it is very difficult to narrow down
specifications among cells because of the large similarities involved with a normal
cell and a cancer cell. Chemotherapy’s antineoplastic effects are most distinctive
throughout the proliferation phases of the cell cycle and these effects jeopardize the
malignant cells growth potential. (Schneider et al., 2003) Therefore, due to the
higher amount of proliferation among cancer cells versus normal cells, a higher
percentage of cancer cells are destroyed compared to normal cells with chemotherapy
drugs. (Schneider et al., 2003)
There are two major classes of antineoplastic agents with chemotherapy that
are classified according to their structure or cell cycle activity. They are cell cycle
phase-specific agents and cell cycle phase-nonspecific agents. (Barton-Burke,
Wilkes, & Ingwerson, 2001) Cell cycle phase-specific agents are designed to destroy
proliferating cells that reside in only the specific phase of the cell cycle (phases G1
through M). (Brown, 1987) Cell cycle phase-nonspecific agents are designed not to
depend on the cell cycle’s phase to be active. (Barton-Burke et al., 2001) In
addition, chemotherapy drugs are categorized based on their function and the cancer
destruction process. For this investigation, the following chemotherapy categories in
Table 3 are the most common in breast cancer survivors at Rocky Mountain Cancer
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Rehabilitation Institute. (Delgin & Vallerand, 2009; Schneider et al. 2003;
www.chemocare.com)
Alkaloids

Table 3. Chemotherapy Categories
Designed to prevent cell duplication by interrupting the
formation of chromosomes.

Alkylating
Agents

Designed to attack all cells in a tumor, whether they are
reproducing or not by binding with the DNA in the cells to
prevent reproduction.

Antimetabolites

Designed to attack the cells during cell division. These
chemotherapy drugs imitate normal cell nutrients so the
cell consumes the drug but eventually starves to death.

Antitumor
Antibiotics

Designed to insert into strands of DNA, either breaking the
chromosomes or inhibiting the synthesis of RNA, which
plays an important role in synthesis within cells.

Anthracyclines

Designed to insert into strands of DNA, either breaking the
chromosomes or inhibiting the synthesis of RNA, which
plays an important role in synthesis within cells. Forms
free-oxygen radicals that destroy DNA and cell
membranes.

Aromatase
Inhibitors

Designed to synthesize estrogen during treatment for breast
and ovarian cancer in postmenopausal women.

Estrogen
Inhibitors

Inhibits topoisomerase and kinase, and interferes with
DNA transcription, replication, and function to prevent
DNA super coiling.

Monoclonal
Antibodies

Designed to bind only to cancer cell-specific antigens and
induce an immunological response against the target cancer
cell.

Progestin

Designed to mirror progestinic effects of progesterone.

Taxanes

Interrupt interphase and mitosis.

The use of a single chemotherapy drug is effective throughout cancer
treatment however; the usage of a mixture (cocktail) of chemotherapy drugs appears
to be more effective. (Schneider et al., 2003) The benefits include paramount cell
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tissue death, where the normal tissue has a higher tolerance of the drugs due to the
lower dosage being used. (Schneider et al., 2003) Another benefit consists of an
expanded realm of drug exposure to the wide assortment of resilient cells. (Schneider
et al., 2003) Yet another benefit consists of a gradual decrement of development
among cancer cells that are resilient to specific treatments during the therapy process.
(Schneider et al., 2003)
Single-agent chemotherapy is the use of one chemotherapy drug throughout
the whole treatment process, while sequential single-agent chemotherapy is the use of
one chemotherapy drug for a period, then switching to a different chemotherapy drug
for another period, and may continue on with other drugs. However, combination
chemotherapy treatment uses two or more chemotherapy drugs at one time
throughout the duration of treatment. Waterhouse, Gelmon, Klasa, Chi, Huntsman,
Ramsay et al. (2006) suggest that the design of combined chemotherapy drugs should
contain the development of certain principles consisting of the following:
1. Each agent in the combination has proven activity as a single agent.
2. Each drug should have a different mechanism of action such that the
combination is additive or synergistic.
3. Toxicities, particularly those that are dose limiting, should not overlap in
order to give the full therapeutic dose of each drug.
4. The best schedule developed for each drug should also be used in the
combination, optimizing the timing of each dosing and minimizing the
time between doses.
5. Resistance mechanisms for each drug should be non-overlapping.
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However, combined chemotherapy is still under continual refinement in the

adjuvant setting for breast cancer and treatments vary by the extent of the disease.
(Waterhouse et al., 2006) In addition, there are a number of patient disease-related
factors to consider when determining whether sequential or combination
chemotherapy treatment is going to be used. Cardoso et al. (2009), suggest that these
factors consist of the following in Table 4 below.
Table 4. Factors to Consider When Choosing Single or Combination
Chemotherapy
Patient related
Disease related
Menopausal status
Biological age and comorbidities
(including organ dysfunction)
Performance status and adverse effects
of prior therapy
Socioeconomic and psychological
factors
Patient preference
Available therapies in the patient’s
country

Endocrine responsiveness
HER2 status
Disease-free interval
Previous therapies and response
obtained
Tumor burden (defined as number
and site of metastases)
Need for rapid disease and/or
symptom control

A significant factor to take into consideration when making the selection of
an appropriate therapeutic strategy in the metastatic setting is the differences in tumor
biology. (Telli & Carlson, 2009) Not only has single and combination chemotherapy
treatment been effective, but also the use of a sequential single-agent chemotherapy
treatment has been suggested to be even more effective than combination
chemotherapy treatment. (Cardoso et al., 2009) However, many studies comparing
combination chemotherapy treatments to single-agent therapy have been limited by
the lack of sequential treatment comparisons. (Telli & Carlson, 2009) Tellie &
Carlson (2009) also suggest that in metastatic breast cancer there are many actively
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used single-agent chemotherapeutic agents, with the majority of the data favoring an
anthracycline- or taxane-based approach.
According to NCCN Clinical Practice Guidelines in Oncology (2010), in the
situation of recurrent or metastatic breast cancer, anthracyclines are considered the
most influential chemotherapy agent in terms of efficacy in breast cancer and are
extensively used in the adjuvant treatment of early-staged breast cancer. Taxanes
(Paclitaxel & Docetaxel) along with anti-metabolites are also preferred categories for
single-agent use. (NCCN Clinical Practice Guidelines in Oncology, 2010) For the
sake of this investigation, the most effective anthracycline drug suggested for
metastatic breast cancer treatment is doxorubicin (adriamycin). (NCCN Clinical
Practice Guidelines in Oncology, 2010; Telli & Carlson, 2009)
Table 5 displays the preferred single-agents and chemotherapy combinations
in an adjuvant chemotherapy setting and for recurrent or metastatic breast cancer,
according to NCCN Clinical Practice Guidelines in Oncology, (2010). For the sake
of this investigation, the chemotherapy single-agents and combinations will only
consist of drugs used with the breast cancer survivors from RMCRI.
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Table 5. Preferred Chemotherapy Regimens in the Adjuvant and Recurrent or
Metastatic Breast Cancer Setting. (NCCN Clincial Practice Guidelines in
Oncology, 2010)
Adjuvant Chemotherapy
Non-Trastuzumab
-TAC
(docetaxel/doxorubicin/cyclophosphamide)
-Dose-dense AC
(doxorubicin/cyclophosphamide) followed
by paclitaxel every 2 weeks
-AC (doxorubicin/cyclophosphamide)
followed by weekly paclitaxel
-TC (docetaxel and cyclophosphamide)
-AC (doxorubicin/cyclophosphamide)
Trastuzumab
-AC followed by T+ concurrent
trastuzumab
(doxorubicin/cyclophosphamide followed
by paclitaxel plus trastuzumab, various
schedules)
-TCH (docetaxel, carboplatin, trastuzumab)
-AC followed by docetaxel + trastuzumab
Other Adjuvant Regimens
-AC followed by docetaxel every 3 weeks
-A followed by T followed by C
(doxorubicin followed by paclitaxel
followed by cyclophophamide) every 2
weekly regimen with filgrastim support
Recurrent or Metastatic Breast Cancer
Single Agents
-Doxorubicin (Adriamycin)
-Paclitaxel
-Docetaxel
-Cyclophosphamide
Agents with Bevacizumab
-Paclitaxel
Chemotherapy Combinations
-AC (doxorubicin/cyclophosphamide)
-AT (doxorubicin/docetaxel;
doxorubicin/paclitaxel)
First-Line Agents for HER2-Trastuzumab + paclitaxel ± carboplatin
Positive Disease
-Trastuzumab + docetaxel
NCCN Clinicial Practice Guidelines in Oncology (2010) recommends

preferred dosages with other chemotherapy drugs and regimens used. The selection,
administration, and modification of these regimens are far too extensive for the sake
of this investigation and will not be discussed. The intervention involved with each
agent and combination for an individual is based on expected toxicities, prior
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treatment, patient individuality, and comorbidity. These regimens have been
modified over time and used in an effective manner and have shown better outcomes
for breast cancer survivors. The following studies suggest evidence for overall
survival, time to treatment failure, disease-free survival, and progression-free survival
in regards to single-agent, sequential-single agent, and combination chemotherapy
regimens used with breast cancer survivors.
Single-Agent vs. Single-Agent Chemotherapy
Sparano et al. (2008) found that the estimated 5-year survival rates were
76.9% for the group receiving paclitaxel every 3 weeks, 81.5% for the group
receiving docetaxel every 3 weeks, and 77.6% for the group receiving weekly
docetaxel. In comparison to the paclitaxel every 3 weeks group, there was a
significantly better disease-free survival in the group receiving weekly paclitaxel
(P=0.006), and in the group receiving docetaxel every 3 weeks (P=0.02), but not in
the group receiving weekly docetaxel (P=0.29). Sparano et al. (2008) also found that
the estimated overall 5-year survival rates were 86.5% for the every 3 weeks
paclitaxel group, 89.7% for the weekly paclitaxel group, and 87.3% for the every 3
weeks docetaxel group. The overall survival was significantly better in the weekly
paclitaxel group (P=0.01) compared to the every 3 weeks paclitaxel group, but not in
the groups receiving docetaxel every 3 weeks (P=0.25) or weekly docetaxel (P=0.80).
Seidman et al. (2008) found that the median time to cancer progression for
patients receiving weekly paclitaxel was prolonged by 4 months (9 vs. 5 months;
P<0.0001), and the addition of trastuzumab to paclitaxel in patients with HER2-2normal breast cancer was not associated with significantly longer time to progression
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(7 vs. 6 months; P=0.28). The adjustment of the line of therapy for the 3-weekly to
weekly paclitaxel showed a significant impact to the overall survival (P=0.009), but
the addition of trastuzumab did not have a significant impact on overall survival.
Forbes et al. (2008) found that over a 5-year adjuvant treatment period, the
time to recurrence was significantly lower for the arimidex group (P=0.002)
compared to the tamoxifen group, and at the 5 year mark, the arimidex group was at a
significantly lower risk (P=0.0001) than the tamoxifen group. However, there were
no differences noted in the overall survival with either group.
Piccart-Gebhart et al. (2006) found that disease-free survival was significantly
greater (85.8%) with the trastuzumab group compared to (77.4%) with the
observational (control) group (P<0.0001), and there was no significance between the
groups regarding the overall survival.
Jones et al. (2005) found that the median time to progression was significantly
longer in the docetaxel every 3 weeks group than in the paclitaxel every 3 weeks
group (P<0.0001), and the median overall survival was significantly longer in the
docetaxel group than in the paclitaxel group (P=0.03).
Paridaens et al. (2000) found that progression-free survival (during and/or
after treatment) in first-line therapy was significantly longer for doxorubicin than for
paclitaxel (median, 7.5 months vs. 3.9 months, respectively; P=0.0001). They also
found that there was no significant difference in the overall survival between the two
study arms (P=0.38), with a median survival of 18.3 months with the doxorubicin
arm and 15.6 months with the paclitaxel arm.
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Chan et al. (1999) found that the median time to treatment failure was

significantly longer in the docetaxel group (22 weeks) than in the doxorubicin group
(18 weeks) using the Wilcoxon test (repeated measures on a single sample) (P=0.01).
They also found that the median overall survival was similar with both treatment
groups (docetaxel, 15 months; doxorubicin, 14 months) with no significant
difference.
The single-agent versus single-agent chemotherapy studies had conflicting
results regarding significant differences in regimen and duration. Sparano et al.
(2008) found that the groups who received paclitaxel and docetaxel every 3 weeks
had a significantly longer duration of disease-free progression compared to the
paclitaxel given weekly. On the other hand, Seidman et al. (2008) found that
paclitaxel given weekly was significantly better in disease-free progression compared
to the group receiving paclitaxel every 3 weeks. However, both studies found that
the weekly paclitaxel group had a significantly longer overall survival period.
Similarly, Jones et al. (2005) and Chan et al. (1999) found that docetaxel
given every 3 weeks produced significantly longer median times to progression, but
Jones et al. (2005) found docetaxel also had a longer overall survival and Chan et al.
(1999) found no significant difference in overall survival. However, Paridaens et al.
(2000) found that doxorubicin given every 3rd week produced a significantly longer
progression-free survival compared to the every 3rd week paclitaxel, but no
significant differences in overall survival.
Forbes et al. (2008) found that arimidex produced significantly less time to
recurrence compared to tamoxifen and no significant difference in overall survival.
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While Piccart-Gebhart et al. (2006) found that trastuzumab produced a significantly
higher disease-free survival compared to the observational group. Sparano et al.
(2008), Seidman et al. (2008) and Jones et al. (2005) were the only studies that found
a significant difference in overall survival.
Combination vs. Combination Chemotherapy
Jones et al. (2006) found that there was a significant increase in disease-free
survival with the docetaxel + cyclophosphamide group (86%) compared to the
doxorubicin + cyclophosphamide group (80%) (P=0.01), but no significant difference
between the groups in overall survival.
Robert et al. (2006) found that the median progression-free survival was
significantly longer in patients receiving trastuzumab + paclitaxel + carboplatin
compared to the trastuzumab + paclitaxel group (P=0.005), and no statistical
significance in overall survival rate.
Romond et al. (2005) found that the trastuzumab + doxorubicin +
cyclophosphamide + paclitaxel group had a greater disease-free survival (87.1%)
compared to the control group using doxorubicin + cyclophosphamide + paclitaxel
(75.4%). However, there was a significantly greater overall survival with the
trastuzumab group (62 deaths) compared to the control group (92 deaths) (P=0.01).
Nabholtz et al. (2003) found that the time to treatment failure was
significantly longer with the docetaxel + doxorubicin group compared to the
doxorubicin + cyclophosphamide group (median, 25.6 weeks vs. 23.7 weeks;
respectively, P=0.04). Overall survival was not different between docetaxel +
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doxorubicin and doxorubicin + cyclophosphamide (median, 22.5 vs. 21.7 months;
respectively).
Henderson et al. (2003) found that there was a significantly greater diseasefree survival rate with the paclitaxel + cyclophosphamide + doxorubicin group
compared to the cyclophosphamide + doxorubicin group (P=0.002), and a
significantly lower death rate for the paclitaxel group compared to the non-paclitaxel
group (adjusted P=0.006; unadjusted P=0.009).
Biganzoli et al. (2002) found that the median progression-free survival was 6
months in the doxorubicin + paclitaxel and doxorubicin + cyclophosphamide arms,
with no significant difference (P=0.65). They also found that the median overall
survival was 20.6 months in the doxorubicin + paclitaxel group compared with
doxorubicin + cyclophosphamide group (20.5 months) with no significant difference
(P=0.49).
All of the studies found significant differences with combination versus
combination chemotherapy except for Biganzoli et al. (2002). Jones et al. (2006) and
Nabholtz et al. (2003) compared 2 regimens with only 2 drugs and had docetaxel in
their regimen. They found significantly longer times to treatment failure, but neither
found significant differences in overall survival.
Robert et al. (2006), Romond et al. (2005) and Henderson et al. (2003)
compared three combined chemotherapy drugs with only two combined
chemotherapy drugs in their studies and all had a significantly longer disease-free
survival period compared with the regimens consisting of only two drugs. In
addition Romond et al. (2005) and Henderson et al. (2003) had significantly longer
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overall survival times with the three drug regimens compared to the two drug
regimens with the exception of Robert et al. (2006). Biganzoli et al. (2002) found no
significant differences with the comparison of two drug regimens.
Combination vs. Single-Agent Chemotherapy
Miller et al. (2007) found that combined chemotherapy (paclitaxel +
bevacizumab) versus single-agent chemotherapy (paclitaxel) significantly increased
the 1-year survival rate (81.2% vs. 73.4%, P=0.01) however; the median overall
survival was similar between the two regimens paclitaxel (26.7 months) and
paclitaxel + bevacizumab (25.2 months) (P=0.16). They also found that the
combined chemotherapy significantly prolonged the progression-free survival
compared to the single chemotherapy (P<0.001).
Marty et al. (2005) found that there was statistical significance in overall
survival for trastuzumab + docetaxel (P=0.03) versus docetaxel alone, and the median
time to treatment failure was significantly greater for combined chemotherapy
(median, 9.8 vs. 5.3 months; P=0.0001) versus single-agent chemotherapy.
Mamounas et al. (2005) found that there was a significant reduction in the
disease-free survival with the paclitaxel + doxorubicin + cyclophosphamide group by
17% compared to the doxorubicin + cyclophosphamide group (P=0.006), and there
was no significant difference between the overall survival rate.
Citron et al. (2003) found that overall survival was significantly prolonged
with dose-dense regimens (II and IV) (P=0.01), (II) Doxorubicin every 2 weeks for 4
cycles followed by paclitaxel every 2 weeks for 4 cycles followed by
cyclophosphamide every 2 weeks for 4 cycles and (IV) Doxorubicin plus
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cyclophosphamide every 2 weeks for 4 cycles followed by paclitaxel every 2 weeks
for 4 cycles. They also found that disease-free survival was significantly prolonged
with dose-dense regimens (II and IV) compared with the every 3-week regimen
(P=0.01).
Sledge et al. (2003) found that overall survival had no significant differences
with median survivals of 19.1 months (doxorubicin), 22.4 months (doxorubicin +
paclitaxel), and 22.5 months (paclitaxel). However, the time to treatment failure was
statistically significant with a longer median for doxorubicin + paclitaxel (8.2
months) compared to either single-agent doxorubicin (6 months) (P=0.002) or singleagent paclitaxel (6.3 months) (P=0.05).
Slamon et al. (2001) found that chemotherapy treatment (paclitaxel +
doxorubicin + cyclophosphamide) combined with trastuzumab compared with
chemotherapy treatment alone (paclitaxel + doxorubicin + cyclophosphamide) had a
significantly longer time to treatment failure (median, 6.9 vs. 4.5 months; P<0.001),
and a significantly longer median survival time 25.1 vs. 20.3 months (P=0.04).
There are conflicting results with the studies mentioned regarding singleagent and sequential single-agent versus combination chemotherapy regimens.
Sledge et al. (2003) found that single agents doxorubicin and paclitaxel compared to
doxorubicin and paclitaxel combined show significantly longer times to treatment
failure, but no significance in overall survival. While Citron et al. (2003) found that
sequential single-agent regimens given every 2 weeks show significantly longer
overall survival and disease-free survival compared to sequential single-agent
regimens given every 3 weeks.
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Mamounas et al. (2005) and Slamon et al. (2001) found that 3 or more drugs

involved with combination regimens given every 3 weeks show significant
improvement in disease-free survival, while Slamon et al. (2001) found results
suggesting a significantly longer overall median survival time.
Miller et al. (2007) and Marty et al. (2005) found that the two drug
combination regimens significantly prolonged time to treatment failure and
progression-free survival compared to single-agent treatment. Miller et al. (2007)
found a significantly longer 1-year survival rate but not overall survival with the
combination regimen. Marty et al. (2005) found significantly longer overall survival
with the combination regimen.
Among all of the studies mentioned regarding single-agent, sequential singleagent, and combination chemotherapy treatment, the results show positive evidence
for all treatment regimens at different times with different dosages. It has been
shown that the treatment seems to be most effective for single-agent, sequential
single-agent, and combination chemotherapy treatment in 3-week intervals (Chan et
al., 1999; Henderson et al., 2003; Jones et al., 2006; Jones et al., 2005; Mamounas et
al., 2005; Marty et al., 2005; Nabholtz et al., 2003; Paridaens et al., 2000; Robert et
al., 2006; Slamon et al., 2001; Sledge et al., 2003; and Sparano et al., 2008). It has
also been suggested that 4-week (Miller et al. 2007) and 2-week intervals (Citron et
al. 2003), as well as weekly intervals (Seidman et al. 2008 and Sparano et al. 2008)
have been effective.
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In addition to the parameters found in the previous research many others such

as toxicities, side effects, mental impairments, and physical impairments are
generally addressed as detrimental factors placed on the body by chemotherapy.
Side Effects and Toxicities
There are substantial side effects with chemotherapy and this plays a
significant role in everyday activities. The most common side effect with
chemotherapy is fatigue (Byar, Berger, Bakken, & Cetak, 2006; De Jong, Courtens,
Abu-Saad, & Schouten, 2002; Donovan, Jacobsen, Andrykowski, Winters, Balducci,
Malik et al., 2004; Patrick, Ferketich, Fram, Harris, Hendricks, Levin et al., 2004)
Fatigue is not a consistent symptom and may appear throughout the cancer treatment
and even months after the treatment process. (Wu, Dodd, & Cho, 2008) Fatigue is a
controversial symptom that hasn’t been fully understood in regards to the
mechanisms. (Wu et al., 2008) However, studies have shown significant
improvement in fatigue with exercise. (Davidson et al., 2005; Hsieh, Sprod, Hydock,
Carter, Hayward, & Schneider, 2008; Schneider, Hsieh, Sprod, Carter & Hayward,
2007; Schwartz, Mori, Gao, Nail, & King, 2001, and Wu et al., 2008)
Throughout the cancer therapy process whether it involves chemotherapy,
hormonal therapy, radiation therapy, or surgery, there is extensive toxicity (sideeffects) involved. Toxicities involved with therapy can occur in the cardiovascular,
immune, pulmonary, gastrointestinal, musculoskeletal, neuroendocrine, and hepatic
systems. (Schneider, Dennehy, Roozeboom, & Carter, 2002) Schneider et al. (2002)
reported that radiation has acute and chronic effects on the cardiovascular systems
involve the pericardium, myocardium, and coronary arteries. In addition,
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chemotherapy agents specifically doxorubicin has been shown to damage the heart by
way of cardiomyopathies (i.e. ischemic, dilated, hypertrophic, restrictive).
(Schneider et al., 2002) Hematopoietic toxicity involves damage to tissues that
produce bone marrow, leucopenia, and granulocytopenia. (Schneider et al., 2002)
Pulmonary toxicity symptoms involve coughing, dyspnea, low-grade fever, fatigue,
low tolerance to exercise, restlessness, and tachypnea. (Schneider et al., 2002)
Abdominal radiation symptoms involved with gastrointestinal system toxicity include
vomiting, nausea, and loss of appetite. Chemotherapy symptoms include nausea and
vomiting which lead to increased energy requirements, nutritional deficiency,
dehydration, electrolyte imbalance, diarrhea, abdominal pain and intestinal disease.
(Schneider et al., 2002) The musculoskeletal effects with radiotherapy and
chemotherapy consist of muscle wasting and cachexia, and tissue necrosis, while
hepatic toxicity symptoms include rapid weight gain, increases in abdominal girth,
fatigue, and anorexia. (Schneider et al., 2002) Neuroendocrine toxicities that stem
from radiotherapy may include cell necrosis and atrophy when relating to thyroid
tissue impairment, while chemotherapy symptoms involve anything from confusion,
memory loss, hearing loss, and drop foot. (Schneider et al., 2002) Lastly,
dermatological toxicities can consist of hair loss, specifically with chemotherapy
drugs. (Schneider et al., 2002)
Exercise Training in Breast Cancer Survivors
Exercise has become increasingly important in our everyday lives and there has
been a plethora of research in regards to its health benefits. Exercise has been shown to
reduce obesity, strengthen cardiovascular capacity, reduce cardiovascular disease,

	
  

35	
  

increase lung capacity and pulmonary function, strengthen bone and muscle, reduce the
effects of aging, increase quality of life, and other alterations. (Brooks et al., 2005)
Exercise programs can also benefit the cancer survivor similar to the healthy individual
but can also improve fatigue, depression, and other debilitating side effects. (Schneider
et al., 2003)
There have been a substantial amount of studies conducted on the effects of
exercise in breast cancer survivors who were currently undergoing chemotherapy
treatment. However, there is limited research investigating the effects of exercise on
cancer survivors taking varying categories of chemotherapy drugs. Most research has
collectively combined all breast cancer survivors regardless of the chemotherapy
treatment. Therefore, the purpose of this investigation was to group survivors according
to their chemotherapy agent and compare exercise test results among the different
categories. The studies in Table 6 show evidence of the effects of exercise, pre- & post(aerobic & resistance training) during and/or after chemotherapy with female breast
cancer survivors.
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Table 6. Exercise Research and Benefits
Matthews et al. Drouin et al.
Courneya et al.
2007
2006
2003
(Randomized
(RCT)
(RCT)
Control Trial)
36
21
53

Hutnick et al.
2005
(Controlled
Clinical Trial)
36

Age
Treatment

51-57
Chemotherapy,
Radiation,
Surgery,
Combination

35-65
Chemotherapy,
Radiation,
Surgery,
Combination

29-69
Chemotherapy,
Radiation,
Surgery,
Combination

Cancer
Treatment
Status
Exercise
Treatment
Assessment

Within last 12
months

Radiation 5
d/wk for 7 wks

50-69
Chemotherapy,
Radiation,
Hormone,
Surgery,
Combination
12 months
before study

12 wks

7 wks

15 wks

Baseline
measurements
from current
activity levels

Modified Bruce
treadmill test

Not applicable

Exercise
Intervention

1st 4 wks
(3 times/wk,
20-30
min/session)
Last 5 wks (5
times/wk, 30-40
min/session)

20-45
min/session,
walking &
treadmill

Cycle
ergometer test
(60 rpm, 2-min
workloads at
30 W w/↑ of
15 W until
pVO2max met
Cycle ergo, 15
min/session for
wks 1-3,
ending at 35
min/session for
wks 13-15

Intensity

Moderate, RPE 50-70% (HRM)
(11-13)
See intervention 3-5 days/wk

70-75%
pVO2max
3 days/wk

60-75%
(HRM)
3 days/wk

Significant
(P=0.01) ↑in
self-reported
walking
Significant
(P<0.01)↑ in
total walking
time (min/wk)

Significant
(P<0.001) ↑ in
pVO2max
w/exercise
group

Increase in
VO2max &
strength, not
significant

Study
&
Type
Subjects

Frequency
Results

Significant
(P<0.001) 6%
median measure
improvement in
pVO2max
w/exercise
group

Study done 2
wks after
treatment
12 wks

40-90
min/session,
aerobic &
resistance
exercise
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Study
&
Type

Mock et al.
2004
(RCT)

Mutrie et al.
2007
(RCT)

Campbell et al.
2005
(RCT)

Subjects

Kolden et al.
2002
(Before & after,
w/out control)
40

108

177

19

Age

45-76

30-69

29-76

Treatment

Chemotherapy,
Radiation,
Hormone,
Surgery,
Combination
Post-surgery

Chemotherapy,
Radiation,
Surgery

Cancer
Treatment
Status

E = 48 (± 10)
C = 47 (± 5)
Chemotherapy, Chemotherapy,
Radiation,
Radiation,
Combination
Combination

58% received
RT
42% received
CT
Either 6 wks for
RT or 12 to 24
wks for CT

~24 wks after
diagnosis

Before &
during study

12 wks, w/24
wk follow-up

12 wks

Exercise
Treatment

16 wks

Assessment

Single-stage
submax
treadmill test,
estimated 1-RM
bench & leg
press test
60 min/session,
Aerobic &
resistance
exercise

12-minute walk
test (Larson et
al., 1996)

12-minute
walk test

12-minute
walk test
(McGavin et
al., 1976)

15-minute walk
to 30-minute
walk over time

45
min/session,
low level
aerobics

40-60%
pVO2max,
↑ to 70% by wk
16
3 days/wk

~50-70%
(HRM)

50-75%
(HRM)

30 minutes
(warm-up,
aerobic/anaero
bic exercise,
cool-down)
60-75%
(HRM)

5-6 times/wk

2 days/wk

Unknown

Significant
(P<0.001) ↑ in
VO2max, bench
& leg press tests

Significant
(P<0.01)
improvement in
increased
functional
capacity

Significant
(P<0.0001)
improvement
in 12-minute
walk

Significant
(P<0.01)
improvement
in 12-minute
walk

Exercise
Intervention

Intensity

Frequency
Results
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Study
&
Type

Pinto et al.
2003
(RCT)

Segal et al.
2001
(RCT)

Thorsen et al.
2005
(RCT)

Turner et al.
2004
(RCT)

Subjects

24

99

111

10

Age

M (52.5)

M (~51)

18-50

33-63

Treatment

Chemotherapy,
Radiation,
Surgery

Chemotherapy, Chemotherapy,
Radiation,
Radiation,
Surgery
Surgery

Cancer
Treatment
Status

Post-surgery

Chemotherapy,
Radiation,
Hormonal,
Combination
During study

Exercise
Treatment

12 wks

26 wks

14 wks

Assessment

Cycle
ergometer peak
test (50 rpm,
w/↑of 25 W
every 2 minutes
60 min/session,
aerobic training,
Last month,
strength training

Modified
Canadian
Aerobic Fitness
Test (mCAFT)

Cycle
ergometer, 50
rpms.

Unknown
min/session,
progressive
walking
program

Intensity

60-70% (HRM)

50-60%
pVO2max

30 minutes
(walking,
resistance
training,
cycling,
aerobics, water
activities,
jogging)
60-70%
(HRM)

Frequency

3 days/wk

5 days/wk

2 times/wk

Aerobic: 7090% (HRM)
Resistance:
moderate
1 time/wk

Results

Significant
(P<0.05 & .01)
↓ in SBP, DBP;
SBP, DBP, &
HR at 75 W
workload

3% & 2% ↑ in
pVO2max with
SDEG & SEG
respectively

VO2max
increased 23%
in intervention
group

No significant
results
regarding
fitness

Exercise
Intervention

Before study

M (17 months
prior to study)
Range 4-60
months
8 weeks, (6
week & 3
month followup)
Submax
bicycle
ergometer test
40-60 minutes,
Low-impact
aerobics,
Resistance
training: 2-3
sets, 8-12 reps
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Study
&
Type

Nikander et al.
2007
(RCT)

Subjects
Age
Treatment

30
41-65
Chemotherapy,
Radiation,
Endocrine,
Combination
Post-treatment

Hsieh et al.
2008
(Pre-test &
Post-test)
96
58
Chemotherapy,
Radiation,
Surgery,
Combination
Complete

12 wks

24 wks

Figure-8 running test
(Gillquist et al., 1986)
50 min/session, aerobic
exercise

Bruce treadmill test

RPE (11-16)
1 day/wk
Significant (P<0.05)
improvement in Figure-8
running & CMJ power

40-75% (HRR)
2-3 days/wk
Significant
(P<0.05) improvement
in treadmill time &
pVO2max

Cancer
Treatment
Status
Exercise
Treatment
Assessment
Exercise
Intervention
Intensity
Frequency
Results

60 min/session, wholebody exercise

Schneider et al.
2007
(Pre-test &
Post-test)
113
56
Chemotherapy,
Radiation
96 completed
RT and/or CT
17 during
24 wks
Bruce
treadmill test
60 min/session,
whole-body
exercise
40-75% (HRR)
2-3 days/wk
Significant
(P<0.05)
improvement
in
treadmill time
& pVO2max

Exercise and Breast Cancer
The studies in Table 6 show research completed on exercise and breast cancer
survivors. Every study involved female breast cancer survivors who had either been on
chemotherapy or were currently receiving chemotherapy treatment before and/or during
the study. Additionally Table 6 shows the results of the exercise tests. As can be seen
other treatments were involved (i.e. radiation, surgery, hormone and endocrine therapy,
and combinations) with these studies, along with different treatment times.
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All of the studies in Table 6 were conducted by a randomized control trial with

the exception of Hutnick et al. 2005 (Controlled Clinical Trial); Kolden et al. 2002
(Before & After w/out a control); Hsieh et al. 2008 (Pre- vs. Post-test); and Schnieder et
al. 2007 (Pre- vs. Post-test). Hsieh et al. 2008 and Schneider et al. 2007 used a preversus post-test design, while Kolden et al. 2002 also used a pre- versus post-test design.
Hutnick et al. 2005 used a controlled clinical trial, not randomized because the attempt of
a blind study wasn’t applicable to their study.
Most of the independent variables with the studies consisted of the effect on
VO2max (Courneya et al., 2003; Drouin et al., 2006; Hsieh et al., 2008; Hutnick et al.,
2005; Kolden et al., 2002; Schnieder et al., 2007; Segal et al., 2001; Thorsen et al., 2005;
and Turner et al., 2004). While Matthews et al. 2007; Mock et al. 2004; Mutrie et al.
2007; and Campbell et al. 2005 measured walking time, and Hsieh et al. 2008; and
Schneider et al. 2007 measured treadmill time in addition to

O2max and Nikander et al.

2007 measured running & counter-movement jump (CMJ) power. Hutnick et al. 2005
and Kolden et al. 2002 also measured strength in addition to

O2max. Lastly, Pinto et

al. 2003 measured systolic and diastolic blood pressure, heart rate, and rate of perceived
exertion.
Significant increases in O2max were found by Drouin et al. (2003), (6%
increase, P<0.001); Courneya et al. (2003), (0.24 ml/min increase, P<0.001); Kolden et
al. (2002), (4.62 ml/kg increase, P<0.001); Hsieh et al. (2008), (P<0.05); and Schneider et
al. 2007, (15% increase, P<0.05); while Hutnick et al. (2005), Segal et al. (2001), and
Thorsen et al. (2005) had increases in O2max but not significant. Significant increases
in meters walked were found by Mutrie et al. (2007), (3% increase, P<0.0001) and
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Campbell et al. (2005), (+328 [± 145], P<0.01) in a 12-minute walk test, while Matthews
et al. (2007) found significant differences in self-reported walking (P=0.01) and total
walking time (from 103 to 134 to 147 min/week, P<0.01). Nikander et al. (2007) found
significant increases in Figure-8 running and counter movement jump (CMJ) (~5% and
~10% respectively, P<0.05) and Hsieh et al. 2008 and Schneider et al. 2007 found
significant increases in treadmill time (37.16%, 27.03%, 28.57%, 33.54% and 1.03 &
1.30 minutes respectively, P<0.05). Mock et al. (2004) found a significant increase in
functional capacity (P<0.01) and Pinto et al. (2003) found significant decreases in
baseline systolic and diastolic blood pressure (-13.55 & -8.89 respectively, P<0.05), heart
rate (-10.78 bpm, P<0.05), and systolic and diastolic blood pressure (-36.45, P<0.01,
-7.77, P<0.05 respectively) at a 75-watt workload. Kolden et al. (2002) found significant
improvement in bench and leg press (11.68 & 60.08 lbs respectively, P<0.001), while
Hutnick et al. (2005) found improvement in muscle strength but not significant. With the
exception of Hutnick et al. (2005), Segal et al. (2001), Thorsen et al. (2005), and Turner
et al. (2004), all of the studies found a significant improvement/increase in exercise preversus post-intervention.
Summary
Breast cancer is the second leading cause of death for women in the U.S.
however; death rates are declining because of modifications in chemotherapy treatment.
Toxicities, physical and mental symptoms will continue to decline as chemotherapy
treatment advances, along with the incorporation of exercise and a healthy diet. Exercise
has been found to be a vital part of the rehabilitation process for breast cancer survivors
and will only continue to support health benefits, wellness, and quality of life.
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CHAPTER III
METHODOLOGY
Experimental Design
There is much research regarding the effects of chemotherapy treatment on breast

cancer survivors. For the sake of this investigation, research concerning specific
chemotherapy drugs used at the Rocky Mountain Cancer Rehabilitation Institute and
suggested evidence for results regarding overall survival; disease-free survival,
progression-free survival, and time to treatment failure will be used. In addition, the
research concerns single-agent, sequential single-agent, and combination chemotherapy
treatments involving the chemotherapy drugs used at RMCRI. Moreover, single-agent
and sequential single-agent will be grouped together and compared to combination
chemotherapy treatment because of the small portion of sequential single-agent
chemotherapy-treated breast cancer survivors who were involved with this investigation
from RMCRI.
The purpose of this research was to determine the differences in physiological
parameters following an exercise intervention in breast cancer survivors on a single
chemotherapy drug versus combination chemotherapy treatment. A secondary purpose
was to determine if differences exist between categories of chemotherapy drugs. The
data for this investigation came from the Rocky Mountain Cancer Rehabilitation Institute
database.
Participants
The study was conducted on fifty-four female breast cancer survivors who had
received either single-agent (n = 34) or combination (n = 20) chemotherapy treatment for
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breast cancer, before, during or after their exercise intervention. The participants were a
convenient sample chosen from the RMRCI database that had completed specific
physiological parameters and pre- and post-exercise assessment. Parameters collected
were age, height, weight, blood pressure, heart rate, forced vital capacity (FVC), forced
expiratory volume (FEV1), predicted O2max (ml/kg/min), time on treadmill, chest press,
latissimuss dorsi pull-down, shoulder press and sit-and-reach.
Exercise Training
The exercise intervention consisted of 3 to 6 months of exercise training between
pre- and post-assessments and included 1-hour sessions, 2-3 days per week, at moderate
intensities involving aerobic and resistance training, flexibility, range of motion, balance,
and stretching. Equipment used during the intervention included the Cybex Exercise
Equipment® (chest press, lat-pull down, shoulder press), Exerstrider® walking poles,
Quinton Q60® treadmill, NuStep, resistance machines, dumbbells, therabands, bosu
balls, fitballs, medicine balls, wall-wheel, wall rope-pulley, dyna disks, and balance pads.
The equipment specifically used for the pre- and post-assessments were the
Cybex Exercise Equipment® (chest press, lat-pull down, shoulder press), Quinton
Medtrack ® treadmill, Spirometrics, Inc. Flowmate Plus pulmonary spirometer, sit-andreach scale, heart rate monitor, blood pressure cuff, stethoscope, pulse-oximeter, and a
metronome.
Collection of Data
The cardiovascular endurance test was conducted using a Bruce Treadmill
Protocol to measure the client’s cardiorespiratory fitness. Table 7 displays the design of
the Bruce Treadmill Protocol VO2peak Test including the stage, speed, and grade. The
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test was terminated based upon the client’s volitional fatigue, whether they asked to stop,
or the assessor’s determination for the termination. In addition, the following is
RMCRI’s guidelines to stop the treadmill test:
1. ACSM’s indications for terminating exercise testing (page 106, 7th edition).
2. Heart rate does not increase with increased intensity.
3. Systolic blood pressure does not increase with increased intensity.
4. Diastolic blood pressure fluctuates more than 10 mmHg from baseline.
5. Oxygen saturation drops below 80 (pulse oximeter).
6. Heart rate exceeds maximum heart rate using the following formula:
HRmax = 205.8 – (0.685 x age).
The time is recorded in the form of a decimal by dividing the seconds by 60 and
the time does not include the warm-up.
Table 7. Bruce Treadmill Protocol VO2peak Test
STAGE
SPEED (MPH)
GRADE (%)
Warm up
1.7
0
1
1.7
10
2
2.5
12
3
3.4
14
4
4.2
16
5
5.0
18
Pulmonary function test involved FEV1% (the amount of exhalation in the first
second) and FVC% (the total volume of air the client can exhale), which are measured
through a dry spirometer. The client is instructed to exhale as forcefully as possible and
then continue exhaling as long as possible without bending at the waist and wearing a
nose clip to prevent any air from passing through the nose. Two test values are obtained
and if the second FVC% score is more than 5% higher or lower than the first FVC%
score, the test must be repeated for a third time. The highest value is used for both
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FVC% and FEV1%. The following standards (norms) are adapted from the American
College of Sports Medicine’s (ACSM) pulmonary function prediction equations:
≥ 95% = Excellent
81-94% = Within normal limits (WNL)
75-80% = Lower limit of normal (LLN)
< 75% = Low
The weight machine protocols (chest, lat-pull down, shoulder) are listed in Table
8 with the predetermined weight percentages for each modality.
Table 8. Percentage of Body Weight To Be Lifted (RMCRI, 2009)
Age: < 45
Age: 45-60
Age: 60-70
Age: > 70
Men
Women Men
Women Men
Women Men
Women
Shoulder .300
.225
.280
.210 .265
.200 .250
.185
press
Lat
.500
.375
.470
.350 .440
.330 .410
.310
Pulldown
Chest
.500
.375
.470
.350 .440
.330 .410
.310
Press
Exercise

The client was instructed to perform a couple of repetitions in order to establish if
more, less, or no weight was to be adjusted. For the weight machine tests, a metronome
was set at 25 bpm (beats per minute). The optimal number of repetitions was established
between 8 and 12 and did not exceed 15. The following exercise tests were instructed by
the assessor to the client for each modality.
A. Shoulder Press
1. Adjust the seat so that when the client grasps the handles, the elbows
are at less than or equal to a 90-degree angle.
2. Have client sit on seat with back and buttocks against the backrest.
3. Feet should be placed flat on the floor and shoulder-width apart.
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4. Full repetition:
UP: Raise training arm until arms are at near full extension.
DOWN: Lower training arm until elbows are at a 90-degree angle.
B. Lateral Pull-Down
1. Have client sit on bench seat with thighs positioned comfortably
underneath the pad.
2. Adjust seat so client’s shoulders line up with the line on the machine.
3. Client’s torso should remain upright throughout the lift (not leaning
forward or backward).
4. Full repetition:
DOWN: Pull training arm down until elbows are at a 90-degree angle.
UP: Allow training arm to rise until arms are at near full extension.
C. Chest Press
1. Adjust the seat so the handles are at mid-chest height.
2. Have client sit on seat with back and buttocks against backrest.
3. Feet should be placed flat on the floor approximately shoulder-width
apart.
4. Full repetition:
UP: Press outward until arms are at near full extension.
DOWN: Lower training arm until elbows are at a 90-degree angle.
D. Modified Sit and Reach Procedure
For the modified sit and reach test, the client sits on the floor with
shoulders, head, and buttocks against a wall and legs straight out in front.
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A 12-inch sit and reach box was placed against the soles of the feet with
the zero end of the yardstick toward the client. The client held her arms
straight forward from the shoulders toward the box, placing one hand on
top of the other and keeping the head and shoulders against the wall. The
yardstick was positioned so that the zero end was touching the fingertips.
The client bent forward, sliding the fingertips along the top of the
yardstick. The client’s knees did not bend and the hands stayed together.
The inches were used at the farthest tip of the fingertips and recorded.
Drug Treatment
The drugs used with the breast cancer survivors for this investigation are

described in Table 9.
Table 9. Chemotherapy Drugs Used With Breast Cancer Survivors at RMCRI.
Drug

Type

Side Effects

How it Works

Arimidex
(Anastrozole)

Aromatase
Inhibitor

Hot flashes,
nausea,
decreased energy
and weakness,
bone pain, &
cough

Blocks the
enzyme
aromatase used
to convert
androgens into
estrogen.
Tumors
dependent on
this hormone
for growth and
will shrink
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Avastin
(Bevacizumab)

Monoclonal
Antibody

Carboplatin
(Paraplatin)

Alkylating
Agent

Cytoxan
(Cyclophosphamide,
Neosar)

Alkylating
Agent

Doxyrubicin
(Adriamycin,
Rubex)

Anthracycl
ine

Exemestane
(Aromasin)

Aromatase
Inhibitor

Generalized
weakness, pain,
abdominal pain,
nausea, vomiting,
poor appetite,
constipation,
diarrhea upper
respiratory
infection,
headache, hair
loss
Low blood
counts, nadir,
nausea, vomiting,
taste changes,
hair loss,
weakness, &
blood test
abnormalities
Low blood
counts, nadir,
hair loss, nausea,
vomiting, poor
appetite, loss of
fertility,
discoloration of
the skin or nails
Pain on side
where medication
was given, low
blood counts,
nadir, nausea,
vomiting, mouth
sores, hair loss
Fatigue, nausea,
hot flashes,
depression, bone
pain, insomnia,
anxiety, shortness
of breath

Interferes with
angiogenesis by
targeting and
inhibiting
human vascular
endothelial
growth factor
(VEGF).

Cell-cycle nonspecific (resting
phase of the
cell)

Cross-links
DNA Cellcycle nonspecific (resting
phase of the
cell); inhibits
DNA synthesis
Non-cell-cycle
specific
(multiple
phases of the
cell), affects
cells only when
they are
dividing
Blocks the
enzyme
aromatase used
to convert
androgens into
estrogen.
Tumors
dependent on
this hormone
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Faslodex
(Fulvestrant)

Estrogen
Inhibitor

Nausea,
vomiting,
weakness, hot
flashes,
headache, bone
pain,
constipation,
abdominal pain,
diarrhea, cough
Hot flashes,
bone/back/joint
pain, nausea,
fatigue, shortness
of breath,
coughing

Femara
(Letrozole)

Aromatase
Inhibitor

Herceptin
(Trastuzumab)

Monoclon
al
Antibody

Fever, body pain,
weakness,
nausea,
headache,
shortness of
breath

Megace
(Megestrol,
Megestrol
Acetate)

Progestin

Weight gain,
edema, menstrual
bleeding

Tamoxifen
(Novaldex)

Estrogen
Inhibitor

Hot flashes,
vaginal
discharge,
swelling, loss of
libido

Blocks estrogen
(interferes with
cell growth)
from going into
the cancer cell

Blocks the
enzyme
aromatase used
to convert
androgens into
estrogen.
Tumors
dependent on
this hormone
Targets the
HER2/neu
receptor on
cancer cells and
prevents cells
from
multiplying
Stops hormone
production,
blocks hormone
receptors
Stops hormone
production,
blocks hormone
receptors;
Interacts with
protein kinase
C and
stimulation of
human NK
cells
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Taxol
(Paclitaxel,
Onxal)

Taxane

Taxotere
(Docetaxel)

Taxane

Low blood
counts,
arthralgias &
myalgias, hair
loss, nausea,
vomiting,
diarrhea,
hypersensitivity
reaction
Low white & red
blood cell count,
nadir, nausea,
hair loss,
diarrhea, mouth
sores, fatigue,
weakness, nail
changes,
peripheral
neuropathy

Mitotic
inhibitor; Cellcycle nonspecific (resting
phase of the
cell)

Mitotic
inhibitor; Cellcycle nonspecific (resting
phase of the
cell)

Table 10 displays the single and combination chemotherapy treatment regimens
used with the breast cancer survivors for this investigation.
Table 10. Single & Combination Chemotherapy Treatment
Single-Agent (n = 34) Combination (n = 20)
Tamoxifen = 23
Arimidex = 8
Taxol = 2
Taxotere = 1

Adriamycin + Cytoxan = 2
Cytoxan + Femara = 1
Carboplatin + Herceptin = 1
Cytoxan + Taxotere = 2
Tamoxifen + Megace = 1
Adriamycin + Cytoxan + Taxotere = 6
Adriamycin + Cytoxan + Tamoxifen = 2
Adriamycin + Cytoxan + Taxol = 2
Adriamycin + Cytoxan + Taxotere + Herceptin = 1
Adriamycin + Cytoxan + Taxotere + Taxol = 1
Adriamycin + Cytoxan + Avastin + Faslodex = 1
Statistical Analyses

The statistical analysis included the dependent variables systolic/diastolic blood
pressure, resting heart rate, treadmill time, predicted O2max, FVC%, FEV1%, chest
press, lat-pull down, shoulder press, and sit-and-reach for single-agent and combination
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chemotherapy clients, pre- versus post-assessment results. Paired t-tests (unequal
variance) were run between single and combination chemotherapy group’s participant
characteristics and significance was established at the 95% confidence interval (P<0.05).
The data analyses were performed with SAS 9.2 and Microsoft Excel.
A Principle Components Analysis (PCA) was conducted to group the variables
into appropriate components based off of a four-factored rotated factor pattern. There
were four variable groups used in the PCA and MANOVA including Pre- and Post-Blood
Pressure (BP), Cardio, Oxygen, and Muscle. Each variable group consisted of the
appropriate physiological variables with the greatest variance among each other. The first
principal component represents for as much of the variability in the data as possible, and
each following component accounts for as much of the remaining variability as possible.
A Multivariate Analysis of Variance (MANOVA) was performed to determine
change over time for the pre- and post-assessment results between overall therapy
category, therapy (Single vs. Combination), and drug (i.e. Taxol vs. Cytoxan + Femara)
categories. A MANOVA was used to find the optimal combination of the dependent
variables and account for the variance associated with the independent variables, which
were then separated out, and each one and interaction on the linear composite was tested.
(Thomas, Nelson, & Silverman, 2005) Differences were considered significant at the
95% level of confidence (P<0.05) and obtained with the Wilks’ Lambda distribution.
The FACTOR Procedure Rotation Method: Varimax for the Pre- and Post-test
data and each variable are presented in Table 14. This statistical method was used to
describe variability among observed variables in terms of a potentially lower number of
unobserved variables (factors). (Thomas et al., 2005)
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CHAPTER IV
RESULTS
INTRODUCTION
The purpose of this research was to determine the differences in physiological

parameters following an exercise intervention in female breast cancer survivors on a
single chemotherapy drug versus combination chemotherapy drugs. A secondary
purpose was to determine any differences in chemotherapy categories.
Data obtained from breast cancer survivors concerning their breast cancer stage,
chemotherapy treatment, exercise test results pre- versus post-training was compiled from
the Rocky Mountain Cancer Rehabilitation Institute at the University of Northern
Colorado. These research data were used in order to answer more questions about
exercise as a therapeutic measure for cancer survivors.
Participant Characteristics
The population used in this investigation included current, past, and deceased
breast cancer survivors who participated in the rehabilitation program at the Rocky
Mountain Cancer Rehabilitation Institute. The study consisted of data from fifty-four
participants who were chosen based on completed physiological results. A combined
fifty-four breast cancer survivors were selected with thirty-four single-agent
chemotherapy treated subjects and twenty combination chemotherapy treated subjects.
Table 11 displays the participant characteristics including the mean of age (years), height
(inches), and weight (pounds). There were no significant differences between singleagent and combination chemotherapy treated groups with the participant’s characteristics.
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All of the pre- and post-assessment results consisted of either three to six-month exercise
interventions.
Table 11. Participant Characteristics
Single-Agent (n = 34) Combination (n = 20)
Age (yrs.)
Height (in.)
Weight (lbs.)

55.80 ± 8.75
64.40 ± 2.66
161.92 ± 37.93

p-value

53.48 ± 6.73
63.72 ± 2.40
159.20 ± 30.21

0.12
0.19
0.67

Note. Values are means ± standard deviation (SD).
Table 12 displays single-agent and combination chemotherapy categories
associated with the chemotherapy drugs used by the breast cancer survivors. Clients
were categorized into one of three therapy categories. The combination group therapy
category 1 had anthracycline, alkylating agent, and taxane drugs. Therapy category 2 had
anthracycline and alkylating agent drugs. Therapy category 3 had no required drug and
was a combination of various drugs. Therapy category 1 was established due to the drug
effect that anthracyclines, alkylating agents, and taxanes have on the body’s
physiological parameters. Therapy category 2, unlike the first, did not involve taxanes,
and therapy category 3 consisted of different combined chemotherapy drugs.
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Table 12. Chemotherapy Categories For Single and Combination Treatments
Single-Agent (n = 34)
Combination (n = 20)
Drug Category = 1
Drug Category = 2
Estrogen Inhibitor = 23
(Therapy Category = 1)

Aromatatse Inhibitor = 8
(Therapy Category = 2)

Taxane = 3
(Therapy Category = 3)

Anthracycline + Alkylating Agent + Taxane = 8
Anthracycline + Alkylating Agent + Taxane + Taxane = 1
Anthracycline + Alkylating Agent + Taxane +
Monoclonal Antibody = 1
(Therapy Category = 1)
Alkylating Agent + Anthracycline = 2
Alkylating Agent + Antrhacycline + Estrogen Inhibitor =
2
Alkylating Agent + Anthracycline + Estrogen Inhibitor +
Monoclonal Antibody = 1
(Therapy Category = 2)
Alkylating Agent + Monoclonal Antibody = 1
Alkylating Agent + Taxane = 2
Alkylating Agent + Aromatase Inhibitor = 1
Estrogen Inhibitor + Progestin = 1
(Therapy Category = 3)
Analysis of Data

Table 13 displays the physiological parameters measured for single and
combination chemotherapy treated breast cancer survivors. The values are presented as
means ± SD and significance is indicated by the p-value. Significance was found in
single and combination groups for FVC%, FEV1%, chest press, lat pulldown, shoulder
press, sit-and-reach, and resting heart rate (combination only). No significant difference
was found in systolic or diastolic blood pressures, resting heart rate for single, treadmill
time, or predicted

O2max.
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VARIABLE

Systole
(mm/Hg)
Diastole
(mm/Hg)
Resting Heart
Rate
(beats/minute)
FVC%
FEV1%
Treadmill
(minutes)
VO2max
(ml/kg/min)
Chest Press
(reps)
Lat Pulldown
(reps)
Shoulder Press
(reps)
Sit-and-reach
(inches)

Table 13. Physiological Parameters
SINGLE (Mean)
COMBINATION (Mean)
(n = 34)
(n = 20)
Pre-Test Post-Test p-value
124.62
124.24 0.86
± 19
± 14
78.24
77.15 0.48
±8
±8
83.53
81.60 0.28
± 11
± 11
93.25
± 15
83.37
± 15
5.81
±2
22.00
±5
9.82
±6
14.40
±8
8.10
±7
12.60
±4

95.29
± 14
87.24
± 14
6.84
±2
24.00
±5
16.32
±7
24.10
± 14
17.30
± 12
13.00
±3

0.001*
0.004*
0.39
0.40
0.001*
0.001*
0.001*
0.01*

Pre-Test Post-Test
124.65
122.20
± 15
± 11
78.20
75.30
±8
±9
94.35
87.75
± 13
± 11
96.90
± 15
91.20
± 15
7.00
±2
22.60
±6
9.85
±4
16.30
± 11
7.75
±6
11.64
±3

102.56
± 12
97.80
± 12
8.20
±2
27.54
±7
16.35
±7
23.20
± 14
17.50
±8
12.19
±4

p-value
0.27
0.21
0.04*
0.006*
0.01*
0.10
0.15
0.006*
0.01*
0.001*
0.04*

Note. Values are means ± SD. * = Differs significantly from pre-test values (P<0.05).
Figures 1 and 2 show the change in pre- to post-assessments for single and
combination chemotherapy treatment regimens, respectively. There was a significant
difference in RHR (combination only), FVC%, FEV%, chest press, lat pulldown,
shoulder press, and sit-and-reach.
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10

*9.20

8
*6.50

Present Change

6
*3.87

4
*2.04
2

2.00
1.03
*0.40

0
-0.38
-2

-1.09
-1.93

-4

Figure 1. Single Chemotherapy (n=34) Present Change Pre- to Post-Assessment.
Note. * = Significance at P<0.05.
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*9.75

10
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*6.60

*6.50

*5.66

6

*6.90

4.94

Present Change

4
1.20

2

*0.55

0
-2
-2.45
-4

-2.90

-6
-8

*-6.60

-10

Figure 2. Combination Chemotherapy (n=20) Present Change Pre- to Post-Assessment.
Note. * = Significance at P<0.05
Table 14 displays the rotated factor pattern for every variable measured. This
statistical method was used to describe variability among observed variables in terms of a
potentially lower number of unobserved variables (factors). The underlined values
represent the variables with the greatest association between each, in each column.
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VARIABLE

Table 14. Rotated Factor Pattern
FACTOR 1 FACTOR 2 FACTOR 3

FACTOR 4

PreBench

0.84970

-0.00762

0.07643

-0.21134

PreLats

0.64599

0.10892

0.08537

-0.04005

PreShoulder

0.63113

0.31693

0.03642

-0.10785

PreSitnreach

0.49203

0.16247

-0.07899

0.04480

PreVO2max

0.32855

0.79911

0.02827

-0.05770

PreTreadmill

0.15472

0.79263

-0.11857

-0.16368

PreFVC

0.04061

0.05559

0.75513

-0.02876

PreFEV

0.20493

0.03203

0.74361

0.04948

PreRHR

-0.15299

-0.17966

0.47781

0.11978

PreExDiastole

-0.14634

-0.00207

0.17362

0.68389

PreExSystole

-0.00362

-0.36504

-0.07966

0.54577

PostTreadmill

0.85954

0.05888

-0.16904

0.00725

PostVO2max

0.84113

0.05877

-0.18282

0.03517

PostSitnreach

0.38934

-0.06245

-0.23875

-0.09422

PostFEV

-0.01597

0.80759

0.02423

-0.01121

PostFVC

0.14330

0.80634

-0.03871

-0.09299

PostRHR

-0.16558

0.37981

0.13591

0.33111

PostExSystole

-0.26394

-0.06570

0.78268

-0.00542

PostExDiastole

-0.19942

0.09612

0.76890

-0.03978

PostLats

0.13001

-0.00477

0.02929

0.67625

PostShoulder

0.02017

0.02674

-0.08226

0.61184

PostBench

-0.14660

-0.05262

0.01534

0.49665

Table 15 displays the overall means and standard deviations of the four variable
group’s factors compared for both single and combination chemotherapy subjects. The
four variable group’s factors consisted of the following:
Blood Pressure (BP) = Systole and Diastole
Cardio = FVC%, FEV1%, and RHR
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Oxygen = Predicted

O2max and Treadmill

Muscle = Bench, Lats, Shoulder, and Sit-and-reach
N
54

Table 15. Means of Four Factor Groups
VARIABLE
MEAN
PreBP
101.61
PostBP
99.97
PreCardio
89.46
PostCardio
90.98
PreOxygen
14.22
PostOxygen
16.13
PreMuscle
9.02
PostMuscle
14.02

STD DEV
11.33
10.32
14.05
12.35
3.87
4.44
4.13
5.39

Table 16 displays the means and standard deviations for all therapy and drug
categories for single and combination chemotherapy subjects pre- and post-assessment.

	
  

60	
  
Table 16. Means By Therapy and Drug Category
THERAPY
DRUG
N
VARIABLE
MEAN
CATEGORY
CATEGORY
1 (Single)

1

2

3

23

8

3

PostBP
PreBP

STD
DEV

102.32
102.90

10.27
12.66

PostCardio
PreCardio

85.82
84.84

13.40
12.96

PostOxygen
PreOxygen

14.73
13.50

3.39
3.94

PostMuscle
PreMuscle

14.03
9.40

5.52
4.16

101.12
102.31

10.62
6.81

PostCardio
PreCardio

91.83
91.37

9.07
14.83

PostOxygen
PreOxygen

14.58
13.95

4.74
3.77

PostMuscle
PreMuscle

15.89
7.75

7.57
3.95

PostBP
PreBP

87.00
87.66

7.00
10.26

PostCardio
PreCardio

94.77
88.55

15.69
9.24

PostOxygen
PreOxygen

19.52
16.59

4.54
4.15

PostMuscle
PreMuscle

10.16
9.00

4.81
4.41

PostBP
PreBP
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2 (Combination)

1

2

3

10

5

5

PostBP
PreBP

97.35
102.45

11.00
12.77

PostCardio
PreCardio

95.90
91.83

7.76
16.29

PostOxygen
PreOxygen

19.87
17.08

4.74
3.79

PostMuscle
PreMuscle

13.23
11.02

4.17
3.12

PostBP
PreBP

96.90
101.70

9.73
5.78

PostCardio
PreCardio

99.60
102.40

13.44
10.89

PostOxygen
PreOxygen

16.33
12.87

2.92
1.40

PostMuscle
PreMuscle

14.04
7.30

3.83
4.18

103.40
101.10

6.06
11.24

PostCardio
PreCardio

92.66
90.53

11.33
13.94

PostOxygen
PreOxygen

15.37
12.14

5.41
3.13

PostMuscle
PreMuscle

14.85
7.08

5.64
5.66

PostBP
PreBP

Figure 3 displays the results from the MANOVA analyses including the overall
therapy category (single versus combination), overall drug category (i.e. single 1 versus
combination 1) and overall therapy category x drug category interaction. No significant
difference was found with any of the MANOVA analyses.
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0.68
0.68

P value

0.66

0.63

0.64

0.61

0.62
0.60
0.58
0.56
Overall Therapy
Category

Overall Drug
Category

Overall Therapy
Category x Drug
Category

Figure 3. Single Versus Combination Chemotherapy MANVOA Results Pre- and PostAssessment.
Summary
The main hypothesis (H1) for this investigation was that breast cancer survivors
receiving single-agent and sequential single-agent chemotherapy treatment would show
significantly greater results in physiological parameters measured in pre- and postexercise assessments compared to breast cancer survivors receiving combination
chemotherapy. H1 was rejected. There were no significant differences between single or
combination chemotherapy treatment pre- and post-assessments. Additionally, H2 was
rejected. There were no significant differences in the chemotherapy categories between
single and combination chemotherapy treatment regimens. H3 was accepted. There were
significant differences (P<0.05) in exercise performance with the single pre- to postexercise assessment and with the combination pre- to post-exercise assessment. The
single and combination groups showed improvements on FVC%, FEV1%, chest press, lat
pulldown, shoulder press, sit-and-reach, and resting heart rate (combination only).
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CHAPTER V
DISCUSSION
Effect of Exercise Training on Breast Cancer Survivors
Many researchers have studied the impact of exercise training on breast cancer

survivors receiving chemotherapy. This investigation is in agreement with Pinto et al.
(2003) concerning a significant decrease in heart rate after exercise. Pinto et al. (2003)
found a significant (-10.78 bpm, P<0.05) decrease in heart rate at a 75-Watt workload,
while this study found a significant (-6.60 bpm, P<0.05) decrease in resting heart rate
with only the combination group. This investigation is also in agreement with Kolden et
al. (2002) concerning a significant (+11.68 lbs, P<0.001) increase in bench press while
this investigation found a significant (Single – change (6.50%) reps, P<0.001;
Combination – change (6.85%) reps, P<0.006) increase in chest press repetitions. This
investigation is in agreement with Hutnick et al. (2005), Thorsen et al. (2005), and Segal
et al. (2001) concerning an increase in

O2max but not significantly.

This investigation is not in agreement with Hsieh et al. (2008), Schneider et al.
(2007), Drouin et al. (2006), Courneya et al. (2003), and Kolden et al. (2002) concerning
a significant increase in predicted

O2max or treadmill time (Hsieh et al. 2008 &

Schneider et al. 2007). This investigation is not in agreement with Pinto et al. (2003)
concerning a significant decrease in systolic and diastolic blood pressure.
However, no research was found in relation to the purpose of this investigation
and whether or not the effect of a single chemotherapy drug regimen versus a
combination chemotherapy drug regimen is more or less effective in response to exercise
tests. This study examined the impact single versus combination chemotherapy regimens
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have on physiological parameters involved with exercise. There were significant
differences (P<0.05) found between pre- and post-assessments within the single and
combination chemotherapy treatment regimens for pulmonary tests FVC% and FEV1%,
chest press, lat pulldown, shoulder press, sit-and-reach, and resting heart rate
(combination only). These findings suggest a beneficial impact exercise has on
physiological parameters measured with breast cancer survivors who have received either
single or combination chemotherapy treatment. These findings also suggest the
similarities between the specific parameters found to be significant with both
chemotherapy treated subjects.
Effect of Single and Combination Chemotherapy Drugs
No significant difference was seen between single and combination chemotherapy
drugs. However, the significant differences found pre- to post-assessment were similar
between single and combination chemotherapy treatment regimens therefore; the
physiological changes were similar between therapy categories pre- to post-assessment.
The following studies found significant differences with breast cancer survivors and
exercise treatment before, during, and after treatment.
Thorsen et al. (2005), Turner et al. (2004), and Courneya et al. (2003) conducted
their studies before treatment and found no significant differences, but Courneya et al.
(2003) found significant (P<0.001) difference in

O2max.

Schneider et al. (2007) and Campbell et al. (2005) conducted their studies before
and during treatment and Schneider et al. (2007) found significant difference in treadmill
time and

O2max (P<0.05) and Campbell et al. (2005) in 12-minute walk (P<0.01).
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Mutrie et al. (2007), Drouin et al. (2006), Mock et al. (2004), and Segal et al.

(2001) conducted their studies during treatment. All but Segal et al. (2001) found
significant differences in (12-minute walk, P<0.0001;

O2max, P<0.001; and Functional

capacity, P<0.01), respectively.
Hsieh et al. (2008), Matthews et al. (2007), Nikander et al. (2007), Hutnick et al.
(2005), Pinto et al. (2003), and Kolden et al. (2002) conducted their studies after
treatment. All but Hutnick et al. (2005) found significant differences in (Treadmill time
&

O2max, P<0.05; Self-reported walking, P=0.01, Total walking time, P<0.01; Figure-

8 running & CMJ power, P<0.05; Systolic/Diastolic blood pressure, P<0.05, Heart rate,
P<0.01; and

O2max, bench & leg press, P<0.001), respectively.

The findings of these investigations suggest that an exercise intervention can
produce a significant improvement at any time throughout the chemotherapy treatment
process. However, no research has been found suggesting significant difference between
single chemotherapy and combination chemotherapy treatment. The findings of no
significance between therapy categories with this investigation may suggest that the
physiological side effects of chemotherapy are similar between therapy categories and
that no one therapy category has more impact on physiological parameters involved with
exercise.
Effect of Chemotherapy Drug Categories
Although slight improvements were found, there were no findings of significant
differences (P=0.63) between chemotherapy drug categories single versus combination
with this investigation. Physiologically, the aforementioned studies suggest exercise
treatment can be found significant at any point in the chemotherapy treatment process.
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However, with this investigation, whether any chemotherapy drug(s) existed in the breast
cancer survivor at the time of the pre- and post-assessment, and if any side effects had
any impact on the breast cancer survivor’s exercise performance, and whether significant
difference could have been found, remains unclear. There has been no research found
concerning chemotherapy drug categories and exercise training with breast cancer
survivors and any interaction between each treatment.
Effect of Interaction Between Drug Therapy and Drug Category
Similarly, even though slight improvements were found, there were no findings of
significant differences (P=0.61) between the interaction of single therapy and drug
categories with combination therapy and drug categories with this investigation. Again,
this may suggest whether the existence of chemotherapy drug(s) the breast cancer
survivor was on may or may not have had an impact with any physiological side effects
and influence on the assessments and intervention. Also, there has been no research
found concerning therapy interaction with chemotherapy drug categories and exercise.
Summary and Conclusions
The findings of this investigation indicate there is a significant benefit in an
exercise intervention program for breast cancer survivors who have received either single
or combination chemotherapy regimens from a pre- to a post-assessment. The findings
also suggest that both single and combination chemotherapy are similar in terms of the
impact an exercise intervention has on either treatment concerning the physiological
parameter’s measured (FEV1%, FVC%, heart rate (combination only), chest press, lat
pulldown, shoulder press, sit-and-reach). In addition, the findings raise the question of
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whether one chemotherapy treatment is more effective than the other and specific
research concerning drugs and categories would be valuable.
Future Study
Further research should be performed specifically concerning chemotherapy
treatment times and encompassing all possible chemotherapy drugs, categories and
combination regimens. In addition, a larger sample size of breast cancer survivors all
starting their exercise intervention and pre- and post-assessments at the same time and
narrowing down the individualized exercise prescriptions to be as close to each breast
cancer survivor as possible should be implemented. Further research should concentrate
on the physiological parameters of major muscle groups, treadmill times, pulmonary
function tests, blood pressure, heart rate, flexibility, and psychological parameters
(fatigue, depression, motivation).
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